Cogent Biosciences Inc Stock News

WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 9,677,420 shares of its common stock at a public offering price of $31.00 per share (suc...

Cogent Biosciences, Inc. soared 120% after positive Phase 3 PEAK study results for bezuclastinib in imatinib-resistant GIST patients. COGT's bezuclastinib showed a 50% reduction in disease progression risk and superior objective response rates versus standard of care. Strong PEAK data de-risks upcoming readouts and supports blockbuster revenue projections, with analysts targeting $1.5bn peak sa...

WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib in 2nd-line GIST. Company's combination therapy showed a significant mPFS improvement (16.5 vs. 9.2 months) and higher ORR (46% vs. 26%) over Sunitinib monotherapy in 2nd-line GIST patients. Upcoming catalysts include NDA filings for GIST in 1H 2026 and NonAdvSM by end of 2025, ...

Cogent Biosciences, Inc. ( COGT ) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 10, 2025 8:00 AM EST Company Participants Christi Waarich - Senior Director of Investor Relations Andrew Robbins - President, CEO & Director Conference Call Participants Neeta Somaiah Anupam Rama - JPMorgan Chase & Co, Research Division Paul Jeng - Guggenh...

Shares of Cogent Biosciences rocketed to a seven-year high Monday on enthusiasm for the company's experimental stomach cancer treatment.

16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p

Phase 3 PEAK results in 2 nd -line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December